Growth Metrics

Neogenomics (NEO) Liabilities and Shareholders Equity (2016 - 2025)

Neogenomics' Liabilities and Shareholders Equity history spans 16 years, with the latest figure at $1.4 billion for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity fell 16.98% year-over-year to $1.4 billion; the TTM value through Dec 2025 reached $5.7 billion, down 12.69%, while the annual FY2025 figure was $1.4 billion, 16.98% down from the prior year.
  • Liabilities and Shareholders Equity reached $1.4 billion in Q4 2025 per NEO's latest filing, down from $1.4 billion in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.9 billion in Q3 2021 to a low of $1.4 billion in Q4 2025.
  • Average Liabilities and Shareholders Equity over 5 years is $1.7 billion, with a median of $1.7 billion recorded in 2023.
  • Peak YoY movement for Liabilities and Shareholders Equity: surged 7379.11% in 2021, then decreased 16.98% in 2025.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $1.9 billion in 2021, then fell by 6.94% to $1.7 billion in 2022, then decreased by 3.38% to $1.7 billion in 2023, then dropped by 2.57% to $1.6 billion in 2024, then fell by 16.98% to $1.4 billion in 2025.
  • Per Business Quant, the three most recent readings for NEO's Liabilities and Shareholders Equity are $1.4 billion (Q4 2025), $1.4 billion (Q3 2025), and $1.4 billion (Q2 2025).